1083326-55-9

Basic information

• Product Name: 2-Chloro-3-phenylsulfonaMidopyridine-5-boronic acid pinacol ester, 96%
• Synonyms: 2-Chloro-3-phenylsulfonaMidopyridine-5-boronic acid pinacol ester, 96%;N-[2-CHLORO-5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-3-PYRIDINYL]-BENZENESULFONAMIDE
• CAS NO: 1083326-55-9
• Molecular Formula: C₁₇H₂₀BClN₂O₄S
• Molecular Weight: 412.69598
• Mol File: 1083326-55-9.mol
• Article Data: 11

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-Chloro-3-phenylsulfonaMidopyridine-5-boronic acid pinacol ester, 96%(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-3-phenylsulfonaMidopyridine-5-boronic acid pinacol ester, 96%(1083326-55-9)
• EPA Substance Registry System: 2-Chloro-3-phenylsulfonaMidopyridine-5-boronic acid pinacol ester, 96%(1083326-55-9)

Safety Data

• Hazardous Substances Data: 1083326-55-9(Hazardous Substances Data)

Upstream product

• 98-09-9 benzenesulfonyl chloride 
• 67443-38-3 5-bromo-2-chloro-3-nitropyridine 
• 588729-99-1 3-amino-5-bromo-2-chloropyridine 
• 15862-34-7 5-bromo-3-nitro-1H-pyridin-2-one 
• 1083326-17-3 N-(5-bromo-2-chloropyridin-3-yl)benzenesulfonamide 
• 73183-34-3 bis(pinacol)diborane 

Downstream Products

• 1092565-28-0 N-(2-chloro-5-{8-[3-(methylsulfonyl)phenyl]-1,5-naphthyridin-2-yl}-3-pyridinyl)benzenesulfonamide 
• 1092565-27-9 N-{2-chloro-5-[8-(4-pyridinyl)-1,5-naphthyridin-2-yl]-3-pyridinyl}benzenesulfonamide 
• 1400667-75-5 N-(2-chloro-5-(4-(tetrahydro-2H-pyran-4-yloxy)pyrido[3,2-d]pyrimidin-6-yl)pyridin-3-yl)benzenesulfonamide 
• 1148008-27-8 N-[2-chloro-5-(quinolin-3-yl)pyridin-3-yl]benzenesulfonamide 

Relevant articles and documents

Bioisosteric replacements of the indole moiety for the development of a potent and selective PI3Kδ inhibitor: Design, synthesis and biological evaluation

Based on indole scaffold, a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, namely FD223, was developed by the bioisosteric replacement drug discovery approach and studied for the treatment of acute myeloid leukemia (AML). In vitro

Development of anti-breast cancer PI3K inhibitors based on 7-azaindole derivatives through scaffold hopping: Design, synthesis and in vitro biological evaluation

Breast cancer is the cancer with the highest incidence all over the world. Phosphatidylinositol 3-kinase is an important regulator of intracellular signaling pathways, which is frequently mutated and overexpressed in majority of human breast cancers, and the inhibition of PI3K has been considered as a promising approach for the treatment of the cancer. Here, we report our design and synthesis of new 7-azaindole derivatives as PI3K inhibitors through the scaffold hopping strategy. By varying the groups at the 3-position of 7-azaindole, we identified a series of potent PI3K inhibitors, whose antiproliferative activities against two human breast cancer MCF-7 and MDA-MB-231 cell lines were evaluated. Representative derivatives FD2054 and FD2078 showed better activity than BKM120 in antiproliferation, reduced the levels of phospho-AKT and induced cell apoptosis. All these results suggested that FD2054 and FD2078 are potent PI3K inhibitors that could be considered as potential candidates for the development of anticancer agents.

Micro-reactor tandem synthesis method of indole anticancer drug molecules

The invention relates to a micro-reactor tandem synthesis method of indole anticancer drug molecules. The method comprises the following steps: a reaction liquid 1 and a reaction liquid 2 are mixed, then are introduced into a first micro-reactor, and are reacted to obtain a first effluent, the first effluent and a reaction liquid 3 are mixed, then are introduced into a second micro-reactor, and are reacted to obtain a second effluent, the second effluent and a reaction liquid 4 are mixed, then are introduced into a third micro-reactor, and are reacted to obtain a final effluent, and the finaleffluent is concentrated and separated to obtain the indole anticancer drug molecules, wherein the reaction liquid 1 is a mixed solution containing 5-bromine-3-amino-2-substituted (R1)-pyridine, the reaction liquid 2 is substituted (R2)-benzenesulfonyl chloride, the reaction liquid 3 is a mixed solution containing bis(pinacolato)diboron, the reaction liquid 4 is a mixed solution containing a 5-bromo-7-azaindole derivative, and the indole anticancer drug molecules are benzenesulfonamidopyridylazaindole compounds. Compared with the prior art, the method of the invention has the advantages of high reaction efficiency, few side reactions and simple production process.